Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 96.77 USD 0.43% Market Closed
Market Cap: 7.3B USD

Merus NV
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Merus NV
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Merus NV
NASDAQ:MRUS
Revenue
$56.6m
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
36%
Pharming Group NV
AEX:PHARM
Revenue
$362.3m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
30%
ProQR Therapeutics NV
NASDAQ:PRQR
Revenue
€16.1m
CAGR 3-Years
65%
CAGR 5-Years
11%
CAGR 10-Years
20%
Uniqure NV
NASDAQ:QURE
Revenue
$15.8m
CAGR 3-Years
-36%
CAGR 5-Years
21%
CAGR 10-Years
7%
argenx SE
XBRU:ARGX
Revenue
$2.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Revenue
$12m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Merus NV
Glance View

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

MRUS Intrinsic Value
HIDDEN
Show

See Also

What is Merus NV's Revenue?
Revenue
56.6m USD

Based on the financial report for Sep 30, 2025, Merus NV's Revenue amounts to 56.6m USD.

What is Merus NV's Revenue growth rate?
Revenue CAGR 10Y
36%

Over the last year, the Revenue growth was 58%. The average annual Revenue growth rates for Merus NV have been 7% over the past three years , 15% over the past five years , and 36% over the past ten years .

Back to Top